On Monday, Oettinger Davidoff AG sent out a press release announcing the retirement of Andreas Schmid as the chairman of the board and the nomination of Domenico Scala in his stead. This change is also accompanied by a new CEO with Beat Hauenstein succeeding to Hans-Kristian Hoejsgaard.
| Domenico Scala | Beat Hauenstein |
|---|---|
 |
 |
| Chairman of the Board | Chief Executive Officer |
Oettinger Davidoff AG’s official press release reads as follow:
Basel, Switzerland, 28 August 2017 – After ten years on the Board of Directors of Oettinger Davidoff
AG, Andreas Schmid (60), company Chairman and shareholder, will leave the company in order to
concentrate on his other roles at various globally active firms and on his own business activities.
The Board of Directors of Oettinger Davidoff AG has nominated Domenico Scala (52) as the new
Chairman.Domenico Scala was responsible as CFO of Syngenta and CEO of Nobel Biocare. Until May 2016,
he chaired the independent Audit & Compliance Committee of FIFA. Currently, he is the Chairman
of Basilea Pharmaceutica, BAK Basel Economics as well as the President of BaselArea, a Member
of the Board of Overseers of Tufts University in Boston and a member of the Bank Council of Basler
Kantonalbank.As part of the ongoing rejuvenation of the operational management, the Board of Directors has also
appointed Beat Hauenstein (50), former COO of the Group, as the new CEO. Hauenstein succeeds
Hans-Kristian Hoejsgaard (59), who has decided to leave the company he has led for seven years
in order to concentrate on his board and consultancy mandates outside the company. The Board of
Directors would like to thank Andreas Schmid and Hans-Kristian Hoejsgaard for their many years of
successful work for the company, and wishes both of them all the best for their personal and
professional future.